Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early versus delayed onset of epoetin alfa in lower-risk MDS with non–transfusion-dependent anemia
2017-000812-41Phase 3Active
- Sponsor
- Groupe Français des Myélodysplasies
- Start
- Oct 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of epoetin alfa in myelodysplastic syndrome (MDS) (2 arms), sponsored by Groupe Français des Myélodysplasies. Primary endpoint: Time to red blood cell transfusion dependence. Started Oct 2017; status: active.
02
Drugs
epoetin alfa
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2017-000812-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000812-41.